Following on from information provided to NICE by the company in December 2020, the appraisal of Rigosertib for previously treated high-risk myelodysplastic syndrome [ID805] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 805

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
21 November 2022 Following on from information provided to NICE by the company in December 2020, the appraisal of Rigosertib for previously treated high-risk myelodysplastic syndrome [ID805] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
21 November 2022 Discontinued. Following on from information provided to NICE by the company in December 2020, the appraisal of Rigosertib for previously treated high-risk myelodysplastic syndrome [ID805] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
15 December 2020 Suspended. Topic is suspended
15 December 2020 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Rigosertib for treating higher risk myelodysplastic syndromes following treatment with hypomethylating agents. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.

For further information on our processes and methods, please see our CHTE processes and methods manual